Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 37 for “"CD20"”.

  1. Estudo da distribuição e quantificação dos linfócitos CD8 e CD20 nas lesões inflamatórias periapicais crônicas

    … quantificar as populações linfocitárias CD8+ e CD20+ em lesões inflamatórias periapicais crônicas. Foram utilizadas 90 lesões inflamatórias periapicais. Através da técnica de imunohistoquímica pelo método da estreptoavidina-biotina, utilizou-se os marcadores CD8 e CD20 para identificação dos …

    brazil-ufrgs Repository record for Estudo da distribuição e quantificação dos linfócitos CD8 e CD20 nas lesões inflamatórias periapicais crônicas (opens in a new tab)

  2. The Selection of Aptamers to CD20 and Their Application as Inhibitors of Complement Dependent Cytotoxicity

    CD20 is an important oncological B-cell marker. Immunotherapy, using anti-CD20 antibodies, has revolutionized the treatment of B-cell cancers. Aptamers are highly specific DNA ligands, raised to identify virtually any target molecule through an iterative process known as SELEX (systematic evolution …

    ottawa-retro Repository record for The Selection of Aptamers to CD20 and Their Application as Inhibitors of Complement Dependent Cytotoxicity (opens in a new tab)

  3. The synergistic interaction between CD20 monoclonal antibodies and Histone Deacetylase inhibitors in B cell Non Hodgkin’s Lymphoma

    … into treatment<br/>paradigms. The anti-CD20 monoclonal antibody, Rituximab, has resulted in<br/>dramatic improvements in survival for patients with B cell Non Hodgkin’s<br/>lymphoma. Histone deacetylase inhibitors are a novel class of anti cancer<br/>agents targeting epigenetic …

    soton Repository record for The synergistic interaction between CD20 monoclonal antibodies and Histone Deacetylase inhibitors in B cell Non Hodgkin’s Lymphoma (opens in a new tab)

  4. Papel del anticuerpo monoclonal anti-CD20 (rituximab) en el tratamiento del lupus eritematoso sistémico refractario al uso de inmunsupresores

    La presente tesis parte de la siguiente hipótesis de trabajo: El uso de Rituximab en pacientes con LES refractarios a inmunosupresores provoca una mejora tanto de los marcadores clínicos, como analíticos, así como, una reducción de los tratamientos coadyu

    sevilla Repository record for Papel del anticuerpo monoclonal anti-CD20 (rituximab) en el tratamiento del lupus eritematoso sistémico refractario al uso de inmunsupresores (opens in a new tab)

  5. Estudio Farmacogenético de la Respuesta al Anticuerpo Monoclonal Anti-CD20 (Rituximab) en el Tratamiento de Pacientes con Linfoma Folicular.

    … un anticuerpo monoclonal quimérico anti-CD20, como inmunoterapia en el tratamiento del linfoma folicular se ha convertido en una terapia esencial, mejorando de forma significativa la supervivencia y presentando un perfil de toxicidad aceptable. Sin embargo, todavía existen dos restos …

    murcia-diss Repository record for Estudio Farmacogenético de la Respuesta al Anticuerpo Monoclonal Anti-CD20 (Rituximab) en el Tratamiento de Pacientes con Linfoma Folicular. (opens in a new tab)

  6. Understanding the Mechanism of Action of Rituximab in the Reversal of Multidrug Resistance in a Non-Hodgkins Lymphoma Cell Line

    It has been previously demonstrated that an anti-CD20 monoclonal antibody (MAb) can reverse MDR in B lymphoma cells in vitro. However, the mechanisms underlying this effect are unknown. A recent study showed that anti-CD20 MAbs could induce rapid redistribution of CD20 into a detergent-insoluble …

    utswmed Repository record for Understanding the Mechanism of Action of Rituximab in the Reversal of Multidrug Resistance in a Non-Hodgkins Lymphoma Cell Line (opens in a new tab)

  7. Potentiating Antibody Therapy by Targeting Complement on Cancer Cells

    … lead to treatment failure. Loss of cell surface CD20 can occur in the treatment of lymphoid malignancies with anti-CD20 antibodies (mAbs) (eg rituximab, ofatumumab) through trogocytosis. This is a frustrated form of phagocytosis, where the target CD20 antigen is removed with a piece of target …

    utswmed Repository record for Potentiating Antibody Therapy by Targeting Complement on Cancer Cells (opens in a new tab)

  8. Chimeric ANTI-CD19 Monoclonal Antibodies for the Treatment of Precursor B Cell Acute Lymphoblastic Leukemia

    … immunotherapies for them are based on anti-CD20 monoclonal antibodies (MAbs). However, CD20 is not expressed on precursor B cell acute lymphoblastic leukemia (pre-B ALL), and CD20 expression is often lost following anti-CD20 immunotherapy. CD19 is a pan B cell membrane antigen that is …

    utswmed Repository record for Chimeric ANTI-CD19 Monoclonal Antibodies for the Treatment of Precursor B Cell Acute Lymphoblastic Leukemia (opens in a new tab)

  9. Probing the sensitivity of autoantibody production to B cell depletion by Rituximab

    … a monoclonal antibody directed against the human CD20 antigen, causes profound depletion of all B cells. When used in patients with autoimmune disease, IgG autoantibody titres often fall whilst serum IgG anti-tetanus toxoid antibody titres are unaffected. Antibodies of both these antibody …

    birmingham Repository record for Probing the sensitivity of autoantibody production to B cell depletion by Rituximab (opens in a new tab)

  10. Die B-Lymphozyten-Aktivierung in der osteoarthrotischen Synovialmembran - ein Beitrag zum molekularpathogenetischen Verständnis der Osteoarthrose

    … B-Zell-Ansammlugen analysiert. Durch CD27/CD20– und CD27/Syndekan-Doppelfärbungen konnte die bevorzugte Lokalisation von Memory-und Plasma-Zellen identifiziert werden. Diese gab nähere Hinweise auf den Ort der Antigen-Aktivierung bei Osteoarthrose. Die Resultate der hohen R/S-Ratios (17/24 …

    wurz-thes Repository record for Die B-Lymphozyten-Aktivierung in der osteoarthrotischen Synovialmembran - ein Beitrag zum molekularpathogenetischen Verständnis der Osteoarthrose (opens in a new tab)

  11. MODULATION OF THE B-CELL REPERTOIRE IN RHEUMATOID ARTHRITIS BY TRANSIENT B-CELL DEPLETION

    … patients were treated with rituximab, an anti-CD20 monoclonal antibody that selectively depletes peripheral CD20+ B-cells for several months. The B-cell repertoire was studied before therapy and at the earliest time point after B-cell regeneration in both patients. A longer follow-up (up to 27 …

    wurz-thes Repository record for MODULATION OF THE B-CELL REPERTOIRE IN RHEUMATOID ARTHRITIS BY TRANSIENT B-CELL DEPLETION (opens in a new tab)

  12. Genomic aberrations as determinants of immune infiltrates in high grade serous ovarian carcinoma

    … IHC protocols against CD3, CD8, FOXP3 and CD20, and quantified the total, tumour and stroma densities of CD3+, CD8+, CD8−, FOXP3+ and CD20+cells in the patient cohort using HALO image analysis software. I also quantified the abundance of other immune cells in the samples using gene …

    cambridge Repository record for Genomic aberrations as determinants of immune infiltrates in high grade serous ovarian carcinoma (opens in a new tab)

  13. Immune Infiltrates in Breast Cancer: Clinical Significance from Histopathology to Prognosis

    … a paucity of information on the significance of CD20+ (B-cells) TILs. To better elucidate the individual prognostic associations of the above TILs, and study the prognostic interplay of each, this thesis aims to evaluate the association between breast cancer-specific survival (BCSS) and CD8+, …

    cambridge Repository record for Immune Infiltrates in Breast Cancer: Clinical Significance from Histopathology to Prognosis (opens in a new tab)

  14. Meningeal B cells in central nervous system autoimmunity: Their phenotype and susceptibility to therapeutic depletion

    … activation status. Following treatment with anti-CD20, B cells were rapidly depleted in peripheral tissues such as the blood, lymph node and spleen, while depletion in the CNS was delayed. Following treatment there was minimal evidence that anti-CD20 accessed meningeal B cells directly, but rather …

    uwo Repository record for Meningeal B cells in central nervous system autoimmunity: Their phenotype and susceptibility to therapeutic depletion (opens in a new tab)

  15. Fc Gamma Receptors Facilitate Antigenic Modulation of LILRB4 and Function as Predictive Biomarkers in Acute Monocytic Leukemia

    … shown to reduce the effector function of anti-CD20 antibodies targeting B cell malignancies.</p> <p>Through this Fc-mediated mechanism, the anti-LILRB4 mAb and others bind their target receptor, inducing internalization of the antigen complex. In the case of anti-LILRB4, this antigenic …

    uthsc Repository record for Fc Gamma Receptors Facilitate Antigenic Modulation of LILRB4 and Function as Predictive Biomarkers in Acute Monocytic Leukemia (opens in a new tab)

  16. Immunzellen in primären und metastasierten gastrointestinalen Stromatumoren (GISTs)

    … Lymphozyten (T-Lymphozyten: CD3, B-Lymphozyten: CD20, NK-Zellen: CD56) in diesen Proben untersucht. Hierzu wurden die Paraffinblöcke der Exzisionspräparate oder der Stanzbiopsien mit Hilfe eines manuellen Tissue-Arrayer in einem Empfängerparaffinblock (TMA) nebeneinander in 22 TMAs aufgereiht. …

    goettingen Repository record for Immunzellen in primären und metastasierten gastrointestinalen Stromatumoren (GISTs) (opens in a new tab)

  17. The role of tissue inflammation in Kenyan women with breast cancer

    … immunohistochemistry for CD3, CD4, CD8, CD68, CD20 and Fox P3, scanned and analysed on the Leica Aperio platform. Cytokine profiles of ER positive and Triple Negative BC were performed using microarray gene arrays and results validated with the ELISA platform. Multivariable polytomous logistic …

    cape-town Repository record for The role of tissue inflammation in Kenyan women with breast cancer (opens in a new tab)

  18. Review of Diffuse large B cell lymphoma, pharmacological aspects of treatment and comparison of outcome between Pre-,Post Rituximab era

    … of NHL which is targeting monoclonal antibody of CD20 and it also shows good prognosis to DLBCL. Rituximab containing chemotherapy regimen like R-CHOP shows relatively good response to DLBCL compare to pre-rituximab era and in rituximab era, overall relative survival rate was significantly …

    debrecen Repository record for Review of Diffuse large B cell lymphoma, pharmacological aspects of treatment and comparison of outcome between Pre-,Post Rituximab era (opens in a new tab)

Page 1 of 2